Indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
Abstract Indoleamine 2, 3-dioxygenase 1 (IDO1) is a heme enzyme that catalyzes the
oxidation of L-tryptophan. Functionally, IDO1 has played a pivotal role in cancer immune …
oxidation of L-tryptophan. Functionally, IDO1 has played a pivotal role in cancer immune …
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Abstract l-Tryptophan (Trp) metabolism through the kynurenine pathway (KP) is involved in
the regulation of immunity, neuronal function and intestinal homeostasis. Imbalances in Trp …
the regulation of immunity, neuronal function and intestinal homeostasis. Imbalances in Trp …
Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
MLJ Watson, PDA Vignali, SJ Mullett… - Nature, 2021 - nature.com
Regulatory T (Treg) cells, although vital for immune homeostasis, also represent a major
barrier to anti-cancer immunity, as the tumour microenvironment (TME) promotes the …
barrier to anti-cancer immunity, as the tumour microenvironment (TME) promotes the …
Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that
regulates various biological processes, including proliferation, metastasis, angiogenesis …
regulates various biological processes, including proliferation, metastasis, angiogenesis …
Modulation of T cells by tryptophan metabolites in the kynurenine pathway
Lymphocytes maturing in the thymus (T cells) are key factors in adaptive immunity and the
regulation of inflammation. The kynurenine pathway of tryptophan metabolism includes …
regulation of inflammation. The kynurenine pathway of tryptophan metabolism includes …
Discovery of IDO1 inhibitors: from bench to bedside
Small-molecule inhibitors of indoleamine 2, 3-dioxygenase-1 (IDO1) are emerging at the
vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide …
vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide …
Targeting the IDO1 pathway in cancer: from bench to bedside
M Liu, X Wang, L Wang, X Ma, Z Gong… - Journal of hematology & …, 2018 - Springer
Abstract Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase
(TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into …
(TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into …
Coordination Polymer‐Coated CaCO3 Reinforces Radiotherapy by Reprogramming the Immunosuppressive Metabolic Microenvironment
Radiotherapy is widely exploited for the treatment of a large range of cancers in clinic, but its
therapeutic effectiveness is seriously crippled by the tumor immunosuppression, mainly …
therapeutic effectiveness is seriously crippled by the tumor immunosuppression, mainly …
Targeting the IDO1/TDO2–KYN–AhR pathway for cancer immunotherapy–challenges and opportunities
JE Cheong, L Sun - Trends in pharmacological sciences, 2018 - cell.com
Indoleamine 2, 3-dioxygenase 1 (IDO1) and tryptophan 2, 3-dioxygenase 2 (TDO2) catalyze
the commitment step of the kynurenine (KYN) metabolic pathway. Traditionally the …
the commitment step of the kynurenine (KYN) metabolic pathway. Traditionally the …
IDO1 in cancer: a Gemini of immune checkpoints
Abstract Indoleamine 2, 3-dioxygenase 1 (IDO1) is a rate-limiting metabolic enzyme that
converts the essential amino acid tryptophan (Trp) into downstream catabolites known as …
converts the essential amino acid tryptophan (Trp) into downstream catabolites known as …